SCHEMBL29388461

SCHEMBL29388461

COc1cccc(NC(=O)/C=C/c2ccc(Cl)cc2)c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 6/20 1.00
MAPT P10636 6/20 1.00
MEN1 O00255 5/20 1.00
TP53 P04637 4/20 1.00
TRPV1 Q8NER1 4/20 1.00
ALDH1A1 P00352 3/20 1.00
CYP3A4 P08684 2/20 1.00
TSHR P16473 2/20 1.00
MAPK1 P28482 2/20 1.00
CYP2C19 P33261 2/20 1.00
HDAC6 Q9UBN7 1/20 1.00
CYP2C9 P11712 1/20 1.00
MMP1 P03956 5/20 0.79
MMP2 P08253 5/20 0.79
MMP9 P14780 5/20 0.79
NPC1 O15118 5/20 0.72
RAB9A P51151 4/20 0.72
SMN1; SMN2 Q16637 4/20 0.72
LMNA P02545 3/20 0.72
NPSR1 Q6W5P4 2/20 0.72

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL296015 1.00 KMT2A (1.00) KMT2AMAPTMEN1TP53TRPV1
SCHEMBL1595342 1.00 KMT2A (1.00) KMT2AMAPTMEN1TP53TRPV1
SCHEMBL247433 0.88 MMP1 (1.00) KMT2AMAPTMEN1TP53TRPV1
SCHEMBL30080242 0.88 MMP1 (1.00) KMT2AMAPTMEN1TP53TRPV1
SCHEMBL247434 0.88 MMP1 (1.00) KMT2AMAPTMEN1TP53TRPV1
SCHEMBL247432 0.88 MMP1 (1.00) KMT2AMAPTMEN1TP53TRPV1
SCHEMBL5793760 0.87 ALDH1A1 (0.77) KMT2AMAPTMEN1TP53TRPV1
SCHEMBL13675628 0.85 TRPV1 (1.00) KMT2AMAPTMEN1TP53TRPV1
SCHEMBL21625686 0.84 MAPT (1.00) KMT2AMAPTMEN1TP53TRPV1
SCHEMBL26458454 0.83 MMP1 (0.78) KMT2AMAPTMEN1TP53TRPV1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 95 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250186375-A1 TREATMENT FOR HOT FLUSHES DIGNITY HEALTH 2025-06-12 US claimed
CN-119955884-A Oat polypeptide extracted by directional enzyme digestion and method and application thereof 杭州恩和生物科技有限公司 2025-05-09 CN claimed
CN-119639852-A Preparation process and application of small fruit coffee grounds derived polypeptides 杭州恩和生物科技有限公司 2025-03-18 CN claimed
US-20250017954-A1 Formulations and Methods for Treating Symptoms of Menopause Kindra Corporation (US) 2025-01-16 US claimed
US-12186314-B2 Compositions and methods for treatment, amelioration, and prevention of anesthesia-induced hypothermia ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) 2025-01-07 US claimed
US-20240408041-A1 COMPOSITIONS AND METHODS FOR TREATING CANNABINOID HYPEREMESIS SYNDROME HABBOUSHE JOSEPH (US) 2024-12-12 US claimed
EP-4433045-A2 FORMULATIONS AND METHODS FOR TREATING SYMPTOMS OF MENOPAUSE KINDRA CORPORATION (US) 2024-09-25 EP claimed
CN-118510501-A Formulations and methods for treating climacteric symptoms 金卓拉公司 2024-08-16 CN claimed
US-12036218-B2 Modulators of airway basal cells for the treatment or prevention of lung diseases Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e. V. (DE) 2024-07-16 US claimed
CN-116966171-A Application of TRPV1 antagonist in preparation of breast cancer treatment drug 南通大学 2023-10-31 CN claimed
WO-2023091628-A2 FORMULATIONS AND METHODS FOR TREATING SYMPTOMS OF MENOPAUSE PG13 LAUNCHPAD ALPHA, INC. DBA KINDRA (US) 2023-05-25 WO claimed
EP-3393462-B1 COMPOSITIONS AND METHODS FOR TREATMENT, AMELIORATION, AND PREVENTION OF ANESTHESIA-INDUCED HYPOTHERMIA UNIV ARIZONA (US) 2023-02-01 EP claimed
CN-114601912-A Itch-caused polypeptide caused by tick and mosquito bites and itch-resisting application thereof 武汉大学 2022-06-10 CN claimed
EP-4048809-B1 SYSTEMS AND METHODS FOR PREDICTING THERAPEUTIC SENSITIVITY TEMPUS AI INC (US) 2026-05-27 EP disclosed
WO-2026087527-A1 NOVEL TRPM4 ANTAGONISTS AND MEDICAL USE THEREOF Universitätsklinikum Hamburg-Eppendorf (DE) 2026-04-30 WO disclosed
EP-4733298-A1 NOVEL TRPM4 ANTAGONISTS AND MEDICAL USE THEREOF Universitätsklinikum Hamburg-Eppendorf (DE) 2026-04-29 EP disclosed
US-20220162198-A1 COMPOSITIONS AND METHODS FOR INCREASING MUSCLE MASS AND OXIDATIVE METABOLISM THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2022-05-26 US disclosed
WO-2022082050-A1 COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF ITCH DUKE UNIVERSITY (US) 2022-04-21 WO disclosed
EP-3952849-A2 COMPOSITIONS AND METHODS FOR INCREASING MUSCLE MASS AND OXIDATIVE METABOLISM THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2022-02-16 EP disclosed
US-11241442-B2 Methods of use for TRP channel antagonist-based combination cancer therapies PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2022-02-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250186375-A1 TREATMENT FOR HOT FLUSHES TRPV1, TRPA1, TRPV2 KMT2A 1037/4885MAPT 2249/4885MEN1 3884/4885
US-20220162198-A1 COMPOSITIONS AND METHODS FOR INCREASING MUSCLE MASS AND OXIDATIVE METABOLISM CPT1B, GYS1, PYGM KMT2A 3365/4885MAPT 4034/4885MEN1 4764/4885
US-20240408041-A1 COMPOSITIONS AND METHODS FOR TREATING CANNABINOID HYPEREMESIS SYNDROME CNR2, TRPV1, CNR1 KMT2A 2248/4885MAPT 3487/4885MEN1 2930/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.